First tablet version of weight-loss jabs to be available in UK in weeks
The daily semaglutide tablet gives adults with obesity or related conditions a private alternative to weekly injections, regulators said.
- On Thursday, the Medicines and Healthcare products Regulatory Agency approved Novo Nordisk's Wegovy pill, offering adults with obesity or related conditions a daily oral alternative to weekly injections.
- Data from the OASIS 4 clinical trial showed adults taking 25mg tablets lost an average of 17 per cent of body weight over 64 weeks, compared to 3 per cent for those on placebo.
- Patients with a Body Mass Index of 30 or above, or those with a BMI between 27 and 30 and related conditions, qualify for the prescription; current 2.4mg injection users can transition directly to daily tablets.
- Novo Nordisk expects the pill available through private providers within weeks, while The National Institute for Health and Care Excellence has not yet assessed it for NHS use, though remains in active dialogue with the company.
- National Pharmacy Association Chair Olivier Picard warned of a 'growing black market for counterfeit weight loss treatments,' as the approval strengthens Novo Nordisk's first-to-market lead against rival Eli Lilly in the expanding obesity drug sector.
37 Articles
37 Articles
Novo Nordisk (NYSE: NVO) Stock Price Surges After UK Becomes First European Nation To Approve Wegovy Weight-Loss Pill
Novo Nordisk (NYSE: NVO) shares climbed 2.7% on Thursday after the UK’s Medicines and Healthcare products Regulatory Agency approved the oral Wegovy pill for chronic weight management in adults. The MHRA authorization covers oral semaglutide 25mg as an adjunct to a reduced-calorie diet and increased physical activity in adults with obesity or overweight and at least one weight-related condition. The approval makes the United Kingdom the first co…
Who can get the new weight loss pill? Everything you need to know about the UK's first approved Wegovy tablet
Britain has become the first country in the United Kingdom to authorise an oral tablet form of the popular weight loss drug semaglutide, marketed as Wegovy.The Medicines and Healthcare products Regulatory Agency granted approval yesterday for what represents a landmark moment in obesity treatment options.This marks the nation's inaugural GLP-1 receptor agonist pill designed specifically for weight management purposes.The decision opens a new cha…
Coverage Details
Bias Distribution
- 50% of the sources are Center
Factuality
To view factuality data please Upgrade to Premium
